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Abstract
Background: The ongoing epidemic of multidrug-resistant tuberculosis (MDR-TB) in Georgia highlights
the need for more effective control strategies. A new regimen to treat MDR-TB that includes pyrazinamide
(PZA) is currently being evaluated and PZA resistance status will largely influence the success of current and
future treatment strategies. PZA susceptibility testing was not routinely performed at the National Reference
Laboratory (NRL) in Tbilisi between 2010 and September 2015. We here provide a first insight into the
prevalence of PZA resistant TB in this region.
Methods: Phenotypic susceptibility to PZA was determined in a convenience collection of well-characterised
TB patient isolates collected at the NRL in Tbilisi between 2012 and 2013. In addition, the pncA gene was
sequenced and whole genome sequencing was performed on two isolates.
Results: Out of 57 isolates tested 33 (57.9%) showed phenotypic drug resistance to PZA and had a single
pncA mutation. All of these 33 isolates were MDR-TB strains. pncA mutations were absent in all but one of
the 24 PZA susceptible isolate. In total we found 18 polymorphisms in the pncA gene. From the two major
MDR-TB clusters represented (94–32 and 100–32), 10 of 15, 67.0% and 13 of 14, 93.0% strains, respectively
were PZA resistant. We also identified a member of the potentially highly transmissive clade A strain carrying
the characteristic I6L substitution in PncA. Another strain with the same MLVA type as the clade A strain
acquired a different mutation in pncA and was genetically more distantly related suggesting that different
branches of this particular lineage have been introduced into this region.
Conclusion: In this high MDR-TB setting more than half of the tested MDR-TB isolates were resistant to
PZA. As PZA is part of current and planned MDR-TB treatment regimens this is alarming and deserves the
attention of health authorities. Based on our typing and sequence analysis results we conclude that PZA
resistance is the result of primary transmission as well as acquisition within the patient and recommend
prospective genotyping and PZA resistance testing in high MDR-TB settings. This is of utmost importance in
order to preserve bacterial susceptibility to PZA to help protect (new) second line drugs in PZA containing
regimens.
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Background
Pyrazinamide (PZA) has been part of the standard first
line TB treatment since the 1980s. Adding PZA to the
treatment regimen had a significant effect on the dur-
ation of treatment needed to cure TB (six instead of nine
months) (reviewed in [1, 2]). Its unique activity against
metabolically inactive, slow growing bacteria make PZA
not only an invaluable component of the current first
line treatment regimen, but also attractive for inclusion
in novel treatment regimens for susceptible TB [3, 4] as
well as for the treatment of drug resistant TB [5]. In
high MDR-TB settings worse treatment outcomes are
observed if the infecting strain is resistant to PZA,
especially when resistance to fluoroquinolones is also
present [6, 7]. It is therefore of utmost importance to
preserve bacterial susceptibility to PZA in order to
ensure the effective treatment of (MDR-)TB.
Drug susceptibility testing (DST) for PZA is not
routinely used to guide (first and second line) anti-TB
therapy. Due to the technical complexity of DST for
PZA the results of phenotypic tests assessing the
susceptibility of TB bacteria to PZA are not always
considered to accurately reflect the resistance status
of the bacteria [8]. The MGIT system is the most
standardised and reliable method to perform DST for
PZA [1, 9] and is currently the only commercially
available phenotypic test to investigate PZA suscepti-
bility. Here, clinical specimens are cultured in the
presence of PZA under acidic conditions mimicking
the in vivo conditions under which pyrazinoic acid
(the activated drug) is active [1]. These issues have
stimulated efforts to inform the design of molecular
assays for the detection of PZA resistance [10, 11]
but these methods are not currently widely applied.
For the reasons explained above the WHO recom-
mends inclusion of PZA in the treatment regimen re-
gardless of the results of PZA susceptibility testing
[12]. Consequently, PZA susceptibility testing is often
not prioritised. As a result there is often only limited
data available on PZA resistance trends and
epidemiology.
Resistance to PZA is largely conferred by mutations
in the pncA gene, which encodes the pyrazinamidase
enzyme that activates the drug [10, 13]. Studies that
have assessed PZA resistance typically report about
40–50% in primary MDR-TB [14–17] and more than
90% in XDR-TB isolates (TBNET) [18]. Alignment of
the protein sequence of PZA from various bacterial
species revealed three conserved regions [19], more-
over three mutational hot spot regions in pncA have
been proposed [20]. However recent systematic
reviews comparing large data sets do not support ex-
tensive clustering of mutations in pncA [10, 11] but
rather define large numbers of high confidence
mutations that when combined can identify molecular
PZA resistance with an accuracy between 89.5 and
98.9% [10]. The observed diversity of pncA mutations
found in clinical PZA resistant strains is in strong
contrast to the limited spectrum of mutations confer-
ring resistance to isoniazid and rifampicin [21, 22].
Clusters of PZA resistant strains with identical pncA
mutations have been reported but so far have been
geographically restricted [23–27]. The presence of
clustered strains all having the same rifampicin- and
isoniazid-resistance conferring mutations but dis-
persed pncA mutations has stimulated the idea that
PZA resistance mutations are acquired post-MDR and
that the presence of PZA conferring mutations could
represent a bottleneck for transmission [28].
The National Tuberculosis Reference centre in Tbilisi,
Georgia, suspended DST for PZA in 2010 (M. Akhalaia/
N. Tukvadze, personal communication) but have re-
sumed DST for PZA in September 2015 (N. Bablishvili,
personal communication). PZA remains an important
component of the standard first line and second line
treatment regimen in this setting. Georgia is recognised
as one of the high-burden MDR-TB countries with
16.6% MDR-TB patients reported among all laboratory
confirmed pulmonary TB patients in 2014 [29]. Al-
though the percentage of new MDR-TB cases remains
constant the percentage of retreatment MDR-TB cases is
increasing. The incidence and prevalence of PZA
resistance is unknown in this setting. Here we report
phenotypic susceptibility and molecular resistance to
PZA in a convenience collection of primary MDR-TB
isolates from Georgia collected between 2012 and 2013.
Material and methods
Patient samples
Samples were part of a larger study of 399 clinical
isolates of newly diagnosed patients with pulmonary
TB collected between 2012 and 2013 at the NCTLD
in Tbilisi, Georgia [30]. Of the 399 samples 67 were
subjected to more detailed genetic investigation.
These samples were selected to reflect the high pro-
portion of MDR-TB strains and strains of the Beijing
genotype previously found in this collection. Coletsos
slopes of all 67 samples were subjected to PZA DST
and Sanger sequencing of the pncA gene. Interpre-
table PZA DST results were obtained for 57 strains.
Two strains were subjected to WGS.
The study was exempt from the approval of the Local
Ethics Committee of the National Center for Tubercu-
losis and Lung Diseases (50 Maruashvili St, 0101 Tbilisi,
Georgia) and Informed Consent was not required as the
patient information used was anonymised before linking
to the results of the analysis of the bacterial cultures and
could not be linked back to individual patients.
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Drug susceptibility testing
Drug susceptibility testing for PZA was performed ac-
cording to the manufacturer’s instructions in the BD
BACTEC MGIT 960 system. Bacteria from an inoculum
of at least one day positive and a maximum of 5 day
positive, according to the BACTEC MGIT, were exposed
to 100 ul/ml PZA in an pH 5.9 environment. A strain
was determined resistant if at the moment when the
growth control (GC) reaches 400 growth units (GU) the
PZA tube had reached at least a 100 growth units.
Sanger sequencing
Of the 57 samples tested by PZA DST 33 samples that
were PZA resistant by DST and all 24 strains that were
susceptible had their pncA gene amplified and sequenced.
The pncA gene was sequenced using pncA_1F: GGC
CGC GAT GAC ACC TCT, pncA_1R: GCC GCA GCC
AAT TCA GCA GT, pncA_2F: CGA AGC GGC GGA
CTA CCA TCA CG and pncA_2R: CCC CAC CTG CGG
CTG CGA ACC and the Sanger sequencing technology
(BaseClear, Leiden, The Netherlands). Sequences were
analysed using BioNumerics (Applied Maths).
Whole genome sequencing
CTAB purified DNA was prepared from isolates 12-
17889 and 12-15893 and whole genome sequences
were prepared at GATC Biotech (GATC, Konstanz,
Germany) on a Illumina HiSeq 2500 device using
paired-end reads of 2x150bp and minimum coverage
of 400 reads in the core genome. The FASTQ files
were mapped to the H37Rv reference genome using
bwa-mem software. From the resulting alignments,
SAMtools and GATK software suites (default para-
meter settings) were used to call SNPs and small
indels, and the intersection of variants between the
methods retained. A full description of the pipeline is
described elsewhere [31, 32]). The strain 12–17,889
was shared with N. Casali (Devision of Infectious Dis-
eases, Imperial College London). Sequence analysis as
well as phylogenetic analysis of strain 12-17889 was
performed as previously described [26].
MIRU-VNTR typing
All 57 samples were typed by 24-locus VNTR [33] either
at the RIVM or by Genoscreen (Lille, France). MLVA
MtbC 15–9 types were assigned using the MIRU-
VNTRplus web application [34] [35] based on the
MIRU-VNTRplus database. A cluster was defined as two
or more strains having the same MLVA type.
Results
PZA DST results were obtained for 57 strains (Fig. 1).
Of these 57.9% (33/57) were resistant and 42.1% (24/57)
were susceptible to PZA. Of the tested 57 strains 63.1%
(36/57) were MDR-TB and 7.0% (4/57) were XDR-TB by
DST (Table 1). These 40 M(X)DR-TB samples represent
54.0% (40/74) of all the M(X)DR-TB isolates identified
in a the larger collection of 399 strains [30]. Of the
remaining 17 strains nine were monoresistant to isonia-
zid and seven were pan-susceptible and one strain was
streptomycin mono-resistant. Of all 57 strains 24 (24/57,
42.1%) were from patients with a previous TB treatment
history and 33 (33/57, 57.9%) were from newly diag-
nosed patients. Of the 24 retreatment cases 17 (17/24,
70%) were PZA resistant and of the 33 new patients 16
(16/33, 48%) were PZA resistant.
A mutation in pncA was found in all 33 isolates that
were identified as PZA resistant by DST (Table 1). In
total 18 different mutations were identified in the 33
PZA resistant strains, of which 17 were non-
synonymous mutations and one strain was identified
with a 1-bp insertion resulting in a frameshift. No pncA
mutations were observed in 23 of 24 PZA susceptible
strains. In one of the 24 PZA susceptible isolates a point
mutation at amino acid position 16 (ATC > CTG) was
identified leading to an I6L substitution. Of the 18 poly-
morphisms identified in pncA 16 have been described
previously in the literature (Fig. 2 and Table 1).
Among the group of 57 strains with interpretable
PZA DST results, four MLVA clusters were identified
two of which contained members with different pncA
mutations (Fig. 3 and Table 4). The largest cluster,
MLVA type 94–32, consisted of 16 strains. Of these,
6/16 (37.5%) were PZA susceptible and had no muta-
tion in pncA; eight strains were phenotypically PZA
Fig. 1 Flowchart of available information. XDR = extensively drug
resistant, MDR = multidrug resistant tuberculosis, INH-R = isoniazid
monoresistant, STR-R = streptomycin mono resistant. a = [30]
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Table 1 Summary of pncA polymorphisms of all 57 strains with interpretable PZA DST results
Strain Nucleotide Substitution DST+[Z]a MTB lineageb MLVA 15–9 type Previously reported Categoryc
12-14129 T14C Ile5Thr MDR+[R] Haarlem 15898-15 No −
12–17,889 A16C Ile 6 Leu MDR+[S] Beijing K1 1065–32 Yes [10] C
12–15893 T20C Val7Ala XDR+[R] Beijing K1 1065–32 Yes [11, 37] −
12–16359 T40C Cys14Arg MDR+[R] Beijing V+/CHIN+ ?-32 Yes [10, 11, 37, 46] A
13–1786 G41A Cys14Tyr XDR+[R] Beijing V+/CHIN+ 100–32 Yes [37, 46] −
12–16734 A146C Asp49Ala MDR+[R] Beijing V+/CHIN+ 100–32 Yes [10, 37, 46] A
12–16077 A188C Asp63Ala MDR+[R] Beijing V+/CHIN+ 100–32 Yes [10, 37] D
12–16119 G204 T Trp68Cys MDR+[R] Haarlem 2943–31 Yes [10] A
12–17593 C211T His71Tyr MDR+[R] Beijing V+/CHIN+ 100–32 Yes [10, 11, 37, 46] A
12–14879
12–17704
12–19027
12–19131
A212C His71Pro MDR+[R] Beijing K1 94–32 Yes [37] −
13–774 A212G His71Arg MDR+[R] Beijing V+/CHIN+ 1047–32 Yes [10, 11, 37, 46] A
12–15175
12–17995
12–18248
12–16269
A212G His71Arg M(X)DR+[R] Beijing K1 94–32 See above See above
12–13963 T254G Leu85Arg MDR+[R] Beijing K1 407–32 Yes [10, 11, 37, 46] A
12–14551 G356 T Trp119Leu MDR+[R] Beijing K1 94–32 Yes [37] −
12–17975 T389G Val130Gly MDR+[R] Beijing V+/CHIN+ 9375–32 Yes [10, 11, 37, 46] A
12–16180 T412C Cys138Arg XDR+[R] Beijing V+/CHIN+ 100–32 Yes [10, 11, 37, 46] A
12–17047 A422C Gln141Pro MDR+[R] Beijing V+/CHIN+ 100–135 Yes [10, 11, 37, 46] A
12–18057
12–17993
12–16295
12–15251
12–18055
12–18893
12–19128
A422C Gln141Pro MDR+[R] Beijing V+/CHIN+ 100–32 See above See above
12–17736 A422C Gln141Pro MDR+[R] Beijing V+/CHIN+ 9368–32 See above See above
12–16850 A422C Gln141Pro MDR+[R] Beijing V+/CHIN+ other See above See above
12–14180 C425T Thr142Met MDR+[R] Beijing K1 94–32 Yes [10, 11, 37, 46] A
12–18166 T448:G Insertion→ frameshift MDR+[R] Beijing V+/CHIN+ 100–32 No −
13–2219 wildtype − MDR+[S] LAM 8013–52 − −
12–17795 wildtype − mono-INH+[S] LAM 843–52 − −
12–16706 wildtype − pan-susceptible + [S] Beijing K1 94–32 − −
12–16496
12–15156
wildtype − mono-INH+[S] Beijing V+/CHIN+ 94–32 − −
12–16505 wildtype − mono-INH+[S] Beijing V+/CHIN+ 407–32 − −
12–17231 wildtype − MDR+[S] Beijing V+/CHIN+ 94–32 − −
12–15460 wildtype − pan-susceptible + [S] Beijing V+/CHIN+ 94–32 − −
13–56 wildtype − MDR-TB+[S] Beijing V+/CHIN+ 100–32 − −
12–18360 wildtype − MDR-TB+[S] Beijing V- 14852–32 − −
12–19069 wildtype − MDR-TB+[S] Euro-American 163–15 − −
12–18493 wildtype − MDR-TB+[S] Beijing K1 94–32 − −
12–15155 wildtype − INHR+[S] Euro-American ?-15 − −
12–13700 wildtype − INHR+[S] Haarlem ?-31 − −
13–2072 wildtype − INHR+[S] Euro-American 12411–15 − −
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resistant and four had a codon 212 mutation leading
to a CAT212CCT (4/16, 25.0%) and four a
CAT212CGT (4/16, 25.0%) change. These eight iso-
lates represented 45.0% (8/17) of MLVA 94–32 strains
among all sequenced isolates. Two other mutations
were identified within this cluster (TGG356 TTG,
ACG425ATG) each in a single isolate (1/16, 6.2%).
The MLVA cluster 100–32 was formed by 14 isolates
of which 13 were phenotypically resistant to PZA. One
isolate was PZA susceptible by DST and did not carry a
mutation in pncA. Seven of the 13 PZA resistant isolates
(7/13, 53.8%) carried the same pncA mutation
(CAG422CCG) and six isolates each (1/13, 7.8%) had
different mutations in pncA (Table 1).
The CAG422CCG mutation resulting in a Gln141Pro
substitution was observed in three MLVA types, 100–32,
100–35 and 9368–32 with the MLVA type 100–32 hav-
ing the most representatives: this mutation was found in
50% (7/14) of all sequenced 100–32 strains.
MLVA clusters 407–32 and 1065–32 were both
formed by two isolates each (Table 1 and Table 4). The
strain carrying the I6L substitution (12–17,889) was one
of two XDR-TB strains in the MLVA 1065–32 cluster.
Unlike the 12–17,889 isolate the other member of the
cluster, isolate 12–15,893, was PZA resistant by DST.
PZA resistance was most likely conferred in 12–15,893
by a mutation in the pncA gene at position GTC20GCC
leading to a V7A substitution. The I6L mutation, found
in the isolate 12–17,889 has been previously reported in
a large set of highly clustered isolates, called clade A,
from Russia [26] together with four other characteristic
genetic markers (rpoB E761D, Peis c-37a, pks15 T46I,
Rv3254 P271P) [26]. In order to investigate whether these
two isolates where part of the clade A cluster the genome
sequences of isolates 12-15893 and 12-17889 were com-
pared to the clade A strains from Russia. All five clade A
specific markers were identified in the genome of strain
12–17,889, the isolate carrying the I6L mutation, but not
in 12-15893. Genetic comparison revealed 43 SNPs
difference between the two isolates (12-15893 and 12-
17889) from this study and four SNPs difference between
12-17889 and the closest neighbour within the previously
determined phylogeny of clade A (Fig. 2 in [26].
Discussion
The high diversity of PZA resistance-conferring muta-
tions reported in TB patient isolates as well as the ab-
sence of confidence in phenotypic testing challenge
routine PZA resistance testing. In addition, it is unclear
what clinical implications there are for the detection of
PZA resistance in vitro. Although, as PZA resistance is
associated with worse outcome, information on (the epi-
demiology of ) PZA resistance will undoubtedly become
increasingly important. Molecular methods aiming to
identify resistance-conferring mutations in pncA seem
more reliable in identifying PZA resistance than
complex DST methods, as the majority of mutations ob-
served in pncA have been shown to confer phenotypic
resistance, albeit in varying levels [10, 11, 36, 37].
Reliable detection of PZA resistance even seems
Table 1 Summary of pncA polymorphisms of all 57 strains with interpretable PZA DST results (Continued)
13–421 wildtype − INHR+[S] Haarlem 7361–31 − −
12–18490 wildtype − INHR+[S] Euro-American 768–26 − −
13–172 wildtype − SR+[S] Beijing V+/CHIN+ other − −
12–15239 wildtype − pan-susceptible + [S] X ?-15 − −
12–15737 wildtype − pan-susceptible + [S] CAS 1059–25 − −
12–16196 wildtype − pan-susceptible + [S] Beijing SA−/CHIN- 785–32 − −
12–18942 wildtype − pan-susceptible + [S] Beijing K1 other − −
13–1 wildtype − pan-susceptible + [S] Beijing V+/CHIN+ other − −
a[Z] = PZA DST, [R] = resistant, [S] = susceptible; b M. tuberculosis lineage according to MLPA; c A = very high confidence resistance mutations, C = mutations with
an unclear role, D = mutations not involved in phenotypic resistance according to [10]
Fig. 2 Distribution of pncA mutations identified in PZA resistant
strains by sequencing and number of mutants per
nucleotide polymorphisms
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achievable using next generation sequencing with
reported sensitivity of between 70.9% to 97% and a spe-
cificity of 94% [38, 39].
Sixteen of the 18 pncA polymorphisms identified in
our study have been described previously [10] and 10/18
and categorized as very high confidence resistance muta-
tions. In our collection of isolates the correlation be-
tween phenotypic testing and genetic analysis was very
good; only one isolate that carried a mutation in the
pncA gene, strain 12-17889, was susceptible to PZA by
conventional DST. This finding was corroborated by a
recent study where the pncA-I6L, mutation was also as-
sociated with susceptibility to PZA in a panel of clus-
tered isolates [26] and was not categorised as a high
confidence resistance mutation [10]. Interestingly, strain
12-17889 was tested phenotypically resistant by an alter-
native method for PZA DST not using low pH [40].
Three pncA mutations, A212G, A212C and A422C,
were observed in multiple isolates. The mutations
A212G and A422C were previously categorised as very
high confidence resistance mutations ([10], Table 1).
These mutations were not only present in closely related
(Beijing) strains (MLVA 94–32 and 100–32) but were
also identified in non-clustered (Beijing) strains. This
may indicate a mild propensity to fix mutations in this
particular locus for specific (Beijing) strains, a
phenomenon called epistasis that we previously investi-
gated but were unable to confirm for rpoB mutations
[22]. The two clusters identified in our dataset (MLVA
94–32 and 100–32) are also known for their epidemic
potential outside of Georgia [41–43].
PZA resistance among new cases as well as clustering of
PZA resistant strains with identical pncA mutations, as we
found here (Table 1, Figs. 3 and 4), suggests that PZA re-
sistant strains are transmissible. Contrary to the majority
of first- and second line drug resistance mutations, mul-
tiple studies show that neither the fitness nor the virulence
are significantly reduced by pncAmutations and data from
Quebec moreover show that pncA mutants can maintain
virulence and transmit [23, 44, 45]. However, as MIRU-
VNTR typing has limited power to discriminate within
genetically very similar strains only the comparison of the
genomes of the respective strains can confirm our obser-
vation and rule out the possibility that the mutations in
pncA have not been individually acquired.
Mutations that confer resistance to rifampicin or
isoniazid and that result in fit transmissible bacterial
strains are significantly more constrained. A very
limited number of rare RIF and INH resistance muta-
tions is found in genetically diverse clinical isolates.
Consequentially, as genetically similar clinical isolates
carry mostly identical MDR mutations (e.g. katG-
S315 T and rpoB-S531 L) a proportion of isolates
with identical MLVA types and these identical MDR
mutations may be the result of independent muta-
tional events rather than transmission of resistant
strains. This is less likely for PZA where the available
pool of fit mutations is much larger. Thus there
might be a tendency to underestimate the de novo
acquisition of rifampicin and isoniazid resistance. A
recent study where longitudinal genomic comparison
was performed supports the repeated acquisition
theory for multiple drugs [25].
In addition to the large clusters, there were two
smaller clusters in our collection, as identified by MLVA:
407–32 and 1065–32. Both clusters consisted of two
members, all of which had acquired different pncA
mutations, indicating independent events. One of the
1065–32 strains, 12-17889, carried an I6L mutation,
which seems specific for a subgroup within the clade A
MDR outbreak strain in the Samara region [26]. The
other 1065–32 strain, 12–15,893, acquired resistance to
PZA most likely via the V7A pncA mutation. Genomic
comparison showed that there were only four SNPs
Fig. 3 Distribution of pncA polymorphisms among the two largest MLVA clusters 94–32 and 100–32. Among all 57 strains with interpretable PZA
DST results four clusters (94–32, 100–32, 407–32 and 1065–32) were identified. Clusters 407–32 and 1065–32 each consisted of two members, all
carrying unique pncA mutations and are therefore not depicted in this figure. Distribution of strains with mutations in the pncA gene and their
respective percentage in the cluster are listed. The legend indicates the position of the mutation in the pncA gene and the nucleotide change. In
cluster 100–32 all but mutation A422C are present in individual isolates. No mutations are shared between the two clusters
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difference between strain 12-17889 and the nearest
neighbour of the clade A cluster, whereas there were 43
SNPs difference between strain 12–17,889 and strain 12-
15893 indicating that they were much more distantly
related.
The high prevalence of PZA resistant strains in
Georgia, a highly endemic MDR(+) region, is a cause for
concern as PZA resistance in MDR-TB cases is associ-
ated with unfavourable treatment outcomes. Bastos et al.
showed that anti-TB treatment was more successful if
patients infected with PZA susceptible MDR-TB
received PZA, this association remained when they
adjusted for fluoroquinolone and/or amikacin/kanamy-
cin resistance [7]. Similar results were found in a study
by Aung et al. showing that additional PZA resistance in
the context of MDR-TB and fluoroquinolone resistance
is associated with a worse treatment outcome [6]. In
addition, PZA resistance may significantly jeopardise any
PZA containing treatment regimens in the future. The
sterilizing capacity of PZA as well as the synergistic
action with drugs such as bedaquilline [3, 4] make it an
attractive drug to include in both first- as well as second
line treatment regimens.
This study has limitations. The isolates tested for PZA
resistance were not specifically sampled for this study but
were part of a previous study. We also did not sequence
genes associated with PZA resistance other than pncA.
Conclusions
We report an alarmingly high percentage of PZA resis-
tance in MDR-TB isolates in Georgia. In this study we see
evidence of both the transmission of pncA resistant strains
as well as the acquisition of PZA resistance in the patient.
This needs to be confirmed by whole genome sequencing
of the respective strains and should also be extended to a
larger study population ideally collected within a larger
time period. Our data contribute to the rising pool of
evidence showing the high incidence of PZA resistance
among MDR-TB isolates. Health authorities and TB con-
trol programs should consider prospective genotyping and
PZA testing to assure current effective MDR-TB treat-
ment and to inform the design of new MDR-TB treatment
trials. Knowledge of PZA resistance in MDR-TB strains is
needed to ensure sufficient active drugs are provided to
protect against the emergence of additional resistance,
particularly against newly introduced drugs.
Fig. 4 UPGMA-tree of isolates with a PZA DST profile. Of all 57 isolates with a PZA DST results, 53 isolates with a valid MIRU-VNTR profile
were included
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